Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1

Interventions

Cisplatin 18Brachytherapy 14Radiotherapy 11Platinum 91,2-diaminocyclohexaneplatinum II citrate 9Radiation 7Paclitaxel 7aldesleukin 6Specimen Handling 6fludarabine phosphate 5fludarabine 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5Colposcopy 5Topotecan 4Immunoglobulin G 4Human Papillomavirus DNA Tests 4Fluorodeoxyglucose F18 4Disulfides 4Biopsy 4Bevacizumab 43-aminopyridine-2-carboxaldehyde thiosemicarbazone 4Trastuzumab 3Taxes 3Nivolumab 3Ipilimumab 3Congresses as Topic 3Carboplatin 3CTLA-4 Antigen 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Uterine Cervical Neoplasms × Technetium Tc 99m Sestamibi × Clear all
NCT00069160 2012-10-12

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
48 enrolled 13 charts
GenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡